Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-11-18 Sale | 2024-11-20 5:00 pm | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 137,803 | $0.2103 | $28,980 | 0 (Direct) | View |
| 2024-09-10 Purchase | 2024-09-12 5:00 pm | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 100,000 | $1.6124 | $161,240 | 124,552 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-10-31 Exercise | 2024-11-04 5:01 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 18,875 | $0 | 137,803 (Direct) | View |
| 2024-10-31 Tax Withholding | 2024-11-04 5:01 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 5,624 | $2.09 | 137,803 (Direct) | View |
| 2024-06-14 Option Award | 2024-06-18 9:26 pm | N/A 2034-06-14 | LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director | 6,696 | $0 | 10,841 (Direct) | View |
| 2024-04-01 Tax Withholding | 2024-04-02 4:54 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 4,732 | $5.12 | 55,219 (Direct) | View |
| 2024-03-31 Exercise | 2024-04-02 4:54 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 15,333 | $0 | 55,219 (Direct) | View |
| 2023-10-31 Exercise | 2023-11-02 4:53 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 18,875 | $0 | 32,826 (Direct) | View |
| 2023-11-01 Tax Withholding | 2023-11-02 4:53 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 6,301 | $2.22 | 32,826 (Direct) | View |
| 2023-06-09 Option Award | 2023-06-13 6:53 pm | N/A 2033-06-09 | LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director | 6,603 | $0 | 9,606 (Direct) | View |
| 2023-04-03 Tax Withholding | 2023-04-04 6:57 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 623 | $2.58 | 7,377 (Direct) | View |
| 2023-03-31 Exercise | 2023-04-04 6:57 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 2,000 | $0 | 7,377 (Direct) | View |
| 2023-02-16 Option Award | 2023-02-21 4:21 pm | N/A N/A | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-10-06 Option Award | 2022-10-11 4:37 pm | N/A 2032-10-05 | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 87,500 | $0 | 87,500 (Direct) | View |
| 2022-06-29 Option Award | 2022-06-30 6:32 pm | N/A 2032-06-29 | LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director | 7,657 | $0 | 7,657 (Direct) | View |
| 2022-02-15 Option Award | 2022-02-17 4:07 pm | N/A 2032-02-14 | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 205,000 | $0 | 205,000 (Direct) | View |
| 2021-10-12 Option Award | 2021-10-13 4:06 pm | N/A 2031-10-11 | Syros Pharmaceuticals Inc. | SYRS | Haas Jason Chief Financial Officer | 750,000 | $0 | 750,000 (Direct) | View |